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Abstract
A number of derivatives and related compounds of lumisantonin were submitted to evalua-
tien for the action of histamine-release inhibition and antiinflammatory effect, as they structurally
resemble guaiazulene in which these actions had been proved. Nineteen compounds of these sup-
pressed 50 per cent or more of the increase in urinary excretion of histamine due to ovomucoid
injection. Five of them markedly inhibited all the edemas in the rat hind paws induced by local
inoculation of dextran, hyaluronidase, histamine, and 5-hydroxytryptamine. Among these com-
pounds, #32(methyl pyrophotosantoninate) showed a superior effect of inhibition than guaiazulene
on all of these edemas, although the effects of two drugs were comparable in the case of oral ad-
ministration. The members showing the edema inhibition likewise evidently protected passive
cutaneous anaphylaxis in guinea pigs by the intraperitoneal administration; the effect of #32 was
more marked than guaiazulene. This effect could be observed when applied to the skin with an
ointment containing the compouhd in a concentration of more than 0.03 per cent 24 hours before.
In vitro histamine releases from the minced lung tissue of sensitized guinea pig elicited by antigen
and sinomenine were both inhibited by these compounds. These findings indicate that the main
sites of the histamine-release inhibition and of the anti-inflammatory effect of these compounds
are in the local tissue. Compound #32 failed to show any analgesic effect in mice, but possessed a
considerable antipyretic action in rats. Some of the compounds in the tests depressed guinea-pig
ileal strip while guaiazulene increased peristalsis, but any of these actions was not recognized with
#32 even in a high concentration. Most of the members effective in inhibiting edemas as well as
histamine release proved to be less toxic than guaiazulene. #32 was well tolerated in the doses
of 6g/kg orally and of 4g/kg intraperitoneally by mice. The growth curves for three weeks of rats
practically did not deviate from that of the controls by daily administration of 1g/kg of #32 by
stomach tube and there were no gross and microscopical abnormalities in the main organs and
blood.
∗PMID: 14008895 [PubMed - OLDMEDLINE] Copyright c©OKAYAMA UNIVERSITY MEDI-
CAL SCHOOL
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Anti~inflammatory and anti-allergic effects of guaiazulene (1, 4-dimethyl-
7-isopropylazulene) werepreviously confirmed through a series of experiments.1.2
In these experiments we found this compound to have an inhibitory action on
the release ,of tissue histamine by various histamine releasers including antigen.
Therefore, it was deduced that this action had an important bearing on the ~e­
chanism of the therapeutic effects. This compound and a few other derivatives
of azulene are widely used in clinics for combatting a variety of inflammatory
and allergic symptoms.
Since lumisantonin has structurally azulene construction, it is interesting
to anticipate a possibility that its derivatives would have guaiazulene-like effects.
For this reason, we have studied a number of lumisantonin derivatives, with
a synthetic co-operation of Dr. 1. SATODA and his co-workers in the Nippon
Shinyaku Research Laboratory, and as the result found some of these to have
anti-inflammatory and anti-allergic effects rather superior to those of guaiazulene
yet less toxic. This paper deals with the results of these studies.
MATERIALS AND METHODS
Compounds tested. Lumisantonin (Fig. 1) and its 72 derivatives as well
as related compounds served as materials. The code number and chemical name
of these compounds are listed in Table 1. Fig. 2 illustrates the structural
formulas of some of these compounds whose histamine-release inhibitory action
proved to be relatively marked as the results of the experiments to be described
later. Most of these compounds were insoluble in water and soluble in alcohol,
but some proved to be insoluble in alcohol.
* Aided by a grant for Fundamental Scientific Research from the Ministry of Education.
t Preliminary communication in Folia pharmacol. japon. 56. 1249. 1960 (in Japanese).
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Table 1. Lumisantonin derivatives and related compounds tested.
I No. I Chemical name 11 No. I Chemical name
Lumisantonin derivatives3- li Guanian-6 : 12.olide derivatives3.8·10
1 Lumisantonin 34 iso-Photosantonic lactone
38 Lumi-6-ePi-santonin 6 iso-Photosantonic lactone acetate
19 Lumisantonin oxime 40 iso-Photo-6-epi-santonic lactone acetate65 a-Dihydro-iso-photosantonic lactone39 Lumi-6-epi-santonin oxime 50 fi -Dihydro-iso-photosantonic lactone
10 Lumisantoninic acid 51 1-Dihydro-iso.photosantonic lactone
2 Dihydrolumisantonin 47 a-Dihydro-iso-photosantonic l';ictone
45 Dihydrolumi-6-epi-santonin acetate
26 Dihydrolumisantonin oxime 66 fi -Dihydro-iso-photosantonic lactone
20 Dihydrolumisantonin semicarbazone acetate
11 Diydrolumisantoninic acid 71 a-Tetrahydro-iso-photosantonic lactone
21 Sodium dihydrolumisantoninate 3 3-0xoguai-4,lO(1)-dien-6: 12-olide
16 3-0xoguai-4,10(1)-dien-6 : 12-olide
22 Dihydrolumisantoninic acid phenylhydrazonebenzylthiouronium salt
17 3-0xoguai-4-en-6 : 12-olide23 Tetrahydrolumisantonin
18 3-0xoguai-4-en-6 : 12-olide semicarbazone61 Tetrahydrolumisantonin acetate 58 3-0xo-6-hydroxyguai-4-en-11-oic acid
49 Tetrahydrolumisantoninic acid 59 Sodium 3-oxo-6-hydroxyguai-4-en-11-oate
57 Dehydrodihydrolumisantoninic acid 25 3-0xoguaian-6: 12.olide
56 Methyl dehydrodihydrolumisantoninate 27 Guaian-6: 12-olide
Pyrolumisantonin derivatives3.li 28 3-Acetoxyguaian-6 : 12-olide
Photosantoninic acid derivativess. '. 7.11
12 Pyrolumisantonin 5 Photosantoninic acid
13 iso-Pyrolumisantonin 69 Photosantoninic acid oxime
42 Dihydropyrolumisantonin 4 Sodium photosantoninate
41 Dihydro-iso-pyrolumisantonin 33 Dimethyl photosantoninate
35 Dehydrobromination product of 60 Dimethyl dehydrophotosantoninate
lumisantonin hydrobromide 15 Pyrophotosantoninic acid
63 iso-Dihydropyrolumisantonin 32 Methyl pyrophotosantoninate
36 Tetrahydropyrolumisantonin 68 Methyl pyrophotosantoninate oxime
64 Dihydro-iso-pyrolumisantonin oxide 14 Pyrophotosantoninic acetic anhydride
67 Dihydroxytetrahydropyrolumisantonin 52 Tetrahydrophotosantoninic aci~
7 Lumisantonin hydrochloride 55 Dimethyl tetrahydrophotosantoninate
72 Dimethyl tetrahydrophotosanto~inate37 Lumisantonin iso-hydrochloride diacetate
8 Lumisantonin iso-hydrobromide 73 Tetrahydropyrophotosantoninic acetic
43 iso-Pyrolumisantonin dibromide anhydride diacetate
62 Bromopyrolumisantonin 70 iso-Pyrophotosantoninic acid
54 Methyl iso-pyrophotosantoninate29 Chlorotetrahydropyrolumisantonin
Photosantonic acid derivatives8•944 10-0xotetrahydropyrolumisantonin
46 I Photosantonic acidiso-Dihydrolumisantonin derivativesS- li 48 Bromophotosan~onic acid
9 iso-Dihydrolumisantonin Othersll
53 iso-Dihydrolumi-6-epi-santonin 24 I Azulene
30 Dihydro-iso-dihydrolumisantonin 31 Oil of Artemisia Kurramensis Q.
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Fig. l. Structural formulas of azulene and lumisantonin.
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Fig. 2. Structural formulas of lumisantonin derivatives and related compounds effective
in inhibiting histamine release in vivo.
Method of testing inhibitory effect on the increased urinary excretion
of histamine induced by ovomucoid in rats. The methods were the same as
employed by YAMASAKI et aP., and KONDO.12 ,13 40 mg/kg of ovomucoid dissolved
in physiological saline solution was intraperitoneally injected into female albino
rats. An increase in the urinary excretion of histamine after this injection is a
reflection of the release of tissue histamine.J2 .13 The relative potency of the com-
pounds inhibiting this increase was sought by the intraperitoneal administration
of 50 mg/kg of each made 2 hours prior to the ovomucoid injection. Control
rats received a similar treatment with 2.5 c.c./kg of physiological saline solution
containing 1 per cent gum arabic used as solvent instead of the compounds.
In six control rats, after the ovomucoid injection the percentage of histamine
3
Yamasaki et al.: Pharmacological studies of lumisantonin derivatives, with special
Produced by The Berkeley Electronic Press, 1961
350 H. YAMASAKI, K. KONDO, T. UDA, T. YAMAMOTO and K. ENDO
excreted in excess of the mean of the histamine excretion in every 30 minutes
before the ovomucoid injection was 312 (301-323). First of all, those compounds
that depressed this percentage below 1/2 in the average of three rats were
selected. Ovomucoid was prepared by MORNER'S method.14
Method of testing inhibitory effect on the edemas of rat hind paw
induced by dextran, hyaluronidase, histamine and 5-hydroxytryptamine.
the techniques of the edema induction and of quantitative expression of the in-
tensity of edemas were reported elsewhere by UDA/6 one of us. The dose used in
the induction of edema was 3 mg for dextran, 20 !J.g for histamine, 0.1 /J.g for
5-hydroxytryptamine (5-HT), and 60 V. U. M. for hyaluronidase. 100mg/kg of
the comPounds to be tested, suspended in physiological saline solution containing
1 per cent gum arabic, was injected intraperitoneally, and edema was produced
in one of the hind paws one hour afterwards by injecting each of the above
mentioned phlogogenic agents beneath the skin of dorsa of the paw. The in-
tensityof the edema of the paw, 1, 2 and 3 hours after the injection of the
agents was compared with that of the control edema at respective time of the
other paw induced 24 hours previously, and the average inhibition rate for 1-3
hours was calculated. In this experiment some of the compounds were given by
mouth as well.'
Method of testing anti-allergic effect. Passive cutaneous anaphylaxis
in guinea pigs was used as the aim of this test. 0.05 C.c. of the serum (Ab-N
20 fJ.g) obtained from 'the rabbit sensitized by ovalbumin recrystallized four times
was inoculated into the center of the depilated abdominal skin of guinea pigs.
Four hours later 50 mg/kg of ovalbumin and 5 c.c./kg of 1 per cent Pelikan India
ink-normal saline solution containing 1 per cent gelatin or 2.5 c.c./kg of 1 per cent
aqueous solution of Trypan blue were concomitantly injected intraventricularly.
In the case of. India ink one hour after the injection and in Trypan blue after
10 minutes, the animals were sacrificed by a blow on the back of the head. The
area colored with injected dyes was measured inside the local skin, and the in-
tensityof coloration and inflammatory changes were also examined. 100 mg/kg
of the drugs to be tested was injected intraperitoneally in a form of the above
mentioned suspension one hour prior to the injection of antigen. With the pur-
pose to determine the efficacy of external application, compound #32 combined
with a mixture of equal volumes of dehydrated lanolin and white vaseline was
smeared on the local skin 24 hours previous to the inoculation of antibody. Most
of other experimental methods were described elsewhere by YAMASAKI et al.1
RESULTS
A. Inhibition of histamine release
In the first step of the screening tests of these compounds the effect of the
4
Acta Medica Okayama, Vol. 15 [1961], Iss. 6, Art. 1
http://escholarship.lib.okayama-u.ac.jp/amo/vol15/iss6/1
Pharmacological Studies of Lumisantonin Derivatives 351
suppression of histamine release in vivo was taken as a criterion. Those com-
pounds that depressed below 1/2 the increase in the urinary output of histamine
after the intraperitoneal injection of ovomucoid in rats, which was 312 in
average as percentage increase in excess of mean controls, with the dose of 50
mg/kg, are shown in Fig. 3. The effect of guaiazulene accompanies in this
fig1,1re for comparison. The structural formulas of these effective lumisantonin
INHIBITOR
HISTAMINE EXCRETION IN EXCESS OF MEAN CONTROL
AS % OF MEAN CONTROL
100 200 300
None
Guoiazutene1------
:# 21
:# 28
# 29
#30
# 32
# 35
., 42 ~
:# 45
# 49
:# 54
#56
# 57
"58
# 62
#64
:# 68
# 69
# 70
# 73
Fig. 3. Inhibitory effect of lumisantonin derivatives and related compounds
on the increase in urinary excretion of histamine induced by intrapedtoneal injection
of 40 mg/kg of ovomucoid in the rat. The compounds (inhibitors) were administered
in dose of 50 mg/kg intraperitoneally one hour prior to ovomucoid injection.
derivatives are presented in Fig. 2. Of these compounds, #32, #42, #49, #57,
#58, and #69 depressed the increased excretion of histamine below 1/3 in more
than two out of three animals.
B. Inhibition of anaphylactoid edema of rat hind paw
Seventeen compounds that proved to be effective in the preceding experi-
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ments were selected for further examination of their efficacy in suppressing the
a~aphylactoid edema induced in a hind paw of rats by dextran, hyaluronidase,
histamine, and 5-HT, with intraperitoneal administration of the compounds in
dose of 100 mg/kg. In Fig. 4 are shown the mean values of percentages of
inhibition as determined at 1, 2 and 3 hours after the induction of edema as the
result of triplicate experiments. The compounds tested yielded a relatively good
- Dextran edema
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I-- l 11\. I I I0 tl i I Io
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Fig. 4. Inhibitory effect of lumisantonin derivatives and related compounds on the
edemas of rat hind paw induced by local injection of dextran, hyaluronidase, histamine and
5-hydroxytryptamine. 100 mg/kg of the compounds was injected intraperitoneally one hour
before edema induction.
effect in inhibiting dextran edema, but the effect on other edemas was variable.
The ones that yeilded a fairly favorable effect on all the four kinds of edema
were # 29, # 32, # 35, # 49 and # 58. The effect of #'32 proved to be superior
to that of guaiazulene in every kind of edemas and was quite apparent even at
a glance (Fig. 5).
The results comparing the effect of oni.l administration of #32 with that of
guaiazulene are illustrated in Table 2 a. In both compounds the effect of oral
administration proved to be weaker than that of the i.ntraperitoneal. When
given three hours prior t~ the induction of edema the oral effect was slightly
more marked than when administered two hours before. The edema inhibiting
effect of these two compounds given in doses of 10-50 mg/kg orally for 5 con-
secutive days before the edema induction was not superior to that obtained by
a single administration of 100 mg/kg as shown in Table 2 b. These results in-
.dicate that .both #32 and guaiazulene are not easily absorbed by the digestive
6
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a. Control b. # 32
Fig. 5. Inhibition of dextran edema of ra!.hind paw. a, control; b, after
intraperitoneal administration of 100 mg/kg of #32.
Table 2. Inhibitory effect of #32 and guaiazulene on dextran edema by oral
administration. Average of duplicate experiments.
a. Effect of single dose of 100 mg/kg
13
21
13
22
15
27
15
23
9
13
2
3
GA
!
Time of edem, I Percent inhibition of edema
Compd. induction after
I I I Imedication (h) 1
h 2h 3h 5h Av. (1.3h )
i
2 I 16
I
16
I
16
I
14
I
16
# 32 !
3
'I
26 I 26 20 I 16 24I
I
b. Effect of repeated administration for 5 days
I
.~~_.- --_._~---
Dose per day Percent inhibition of edema
! Compd. (mg/kg) 1h 2h 3h 5h Av. (1_3h )
10 4.5 3.5 2 3 3
#32
50 13 13 17 14 14
GA
10 0.5 3.5 1 -1.5 1.7
50 9 20 17 15 15
canal.
C. Effect on passive cutaneous anaphylaxis (PCA)
The eight lumisantonin derivatives that yielded a relatively marked effect
on three or more kinds of edema in the above experiments as well as guaiazu-
lene were submitted to the test for their preventive effect on peA in guinea pigs
by the intraperitoneal administration of 100 mg/kg dose. The results are shown
in Table 3, where the intensity of the coloration with dyes in the inner surface
of the skin is represented as follows. The coloration visible through a cellophane
7
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Table 3. Inhibitory effect of lumisantonin dervatives on passive cutaneous anaphylaxis
in guinea pigs. Each compound was administered intraperitoneally in
100 mg/kg one hour before antigen injection.
~mpd·IDy:1 11nreT fl'Area of coloration (cm2 ±S.E.) sltyof n tmcolora- ha ory
tion c anges
Control I 20.2, 23.7, 26.4, 19.3, 20.2, 19.4, 23.9, 20.1 Av. 4 320.3, 28.5, 17.3, 20.8, 26.4, 18.5, 18.6····· .. · .... 21.6±0.3
/I T 26.4, 17.8, 18.0, 16.8 .... ·.. ·.. ·.. ·· ...... · ................ 19.8 4 3
GA I 15.1, 8.3, 10.4, 3.5, 1.1, 8.8·· .............. ·.. · 7.9±2.3 1 1
/I. T 13.7, 12.5, 6.5···· .... ·· ........ ···· .. ·.. ·.. ···· .. ·.. ···· .. ·· 10.9 2 2
#28 I 5.4, 14.8, 7.7, 20.8, 9.8, 9.8 .................... 1l.4±2.3 2 3
#29 I 18.2, 12.6, 19.3, 13.8, 16.8, 6.1 .................... 14.7±2.7 2 2
#32 I 3.0, 2.4, 1.8, 3.8, 4.5, 4.8 .................... 3.4±0.9 1 2
1/ * I 10.1, 17.8, 14.0, 15.2, 17.7, 17.0·· ...... · .......... · 15.3±1.31 3 2
1/ T 7.2, 1.9, 11. 4 ............................................. 6.8 2 1
#35 I 14.5, 10.8, 14.2, 2.9, 11.1, 11.9·· .............. · .... 1O.9±1.7 3 2
#42 I 6.6, 12.6, 13.0, 3.8, 20.2, 3.0· .. · ............ ·· .. 9.9±2.7 2 2
#49 I 15.5, 7.8, 6.5, 10.7, 9.8, 15.5 .................... 1l.0±2.6 2 2
#54 I 13.5, 13.4, 4.3, 18.2, 19.5, 8.4 ...... ·........ ·.... 12.9±2.4 3 2
#58 I 17.6, 18.5, 15.7, 13.5, 17.7, 14.7· .... · .. ·.. · ........ 16.3±0.8 3 2
* By stomach tube, the same dose; t I : India ink test, T: Trypan blue test.
a. Control b. # 32
Fig. 6. Inhibition of passive cutaneous anaphylaxis in the guinea pig by #32.
a, control; b, after intraperitoneal injection of 100 mg/kg of # 32 prior to antigen
injection. India ink test.
paper at a distance of 20 cm as 4, that visible in the same way at a distance of
10 cm as 3, that is not visible by this method but clearly visible macroscopically
8
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as 2, and that is extremely weak as 1. As for the intensity of inflammatory
reaction, the ones that showed marked hemorrhage, congestion and edema
,Y\"ere classified as 3, those showing these changes slightly as 2, and the ones that
revealed congestion only as 1.
Everyone of the compounds tested clearly diminished the coloration area,
which: was in control 19.8 cm2 av€:?!age for Trypan blue test, and 21.6 cm2 for
India ink test, and also demonstrated corresponding effects of inhibition of the
intensity of coloration and of inflammatory reactions. Among these compounds
the one that yielded the most suppressive effect was compound #32, and this
qrug :Qiminished the coloration area down to 1/3 to 1/4 of the control. This
effect is even more potent than guaiazulene. Fig. 6 reveals this marked effect
"1 ,,:. '"
of compound #32. Although th~ effect is much weaker in the case of oral
~dmin~stration, still it can distinctly be seen (* in Table 3). Following compound
#32, the PCA-preventing effect diminished in the order of compounds #42,
#35, 149, #28, #54, #29, and #58.
" Ointment containing compound #32 in the concentrations of 1: 1, 000,
1: 3, qoO and 1: 10,000 was applied on the 4 9112 area of the depilated skin of
the abdomen of guinea pigs for 24 hours, and PeA was induced by inoculating
~nti1xx:ly into the skin at the center of the area. As shown in Table 4, #32 in
concentrations over 1: 3, 000 revealed a distinct inhibition of PCA, and at
i: 1, 000 the coloration area was diminished down to about one half of the
control in the animals receiving the application of the base of ointment only.
Table 4. Effect of local application o~ #32 on passive cutaneous anaphylaxis in guinea
pigs. #32 containing ointment was smeared on the depilated skin of abdomen
24 hours prior to induction of PCA. Antibody was inoculated into the
skin of the center of pretreated area. India ink test.
Concn. of
I
[Int:!'ity I Inflam-co~pd. Area of coloration (cm2±S. E. ) matorycoloratIon changes
Control Av.
\Base alone) 21.3, 19.6, 19.3, 20.0, 24.1, 21.3, 23.9" 21.4±O.7 4 3
1 : 1000 10.1, 10.3, 10.5, 9.1. 10.2, 14.2, 18.0 .. 11.4±1.1 2 2
1 : 3600 16.2, 17.5, 19.0, 17.6, 16".8, 19.0 ........... 17.7±O.5 2 2
1: 10000 22.3, 21.2, 19.2, 18.1, 19:0' 19.8 ........... 19.8±1.3 4 3
D. Inhibition of histamine r,.elease from sensitized guinea-pig lung
by antigen and chemical histamine releasers
A certain number of lumisantonin derivatives clearly suppressed the increase
in urinary excretion of histamine in rats caused by ovomucoid injection. This
is an indication of the inhibitory action of these compounds on in vivo histamine
rel~ase due to ovomucoid.lS However, ovomucoid is the releaser specific to this
9
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Table 5. Inhibition of in vitro histamine release by lumisantonin derivatives. Histamine
was released from chopped lung tissue of a: sensitized guinea pig by egg-albumin
(antigen) or chemical histamine releasers. Concentration of releasers: egg-
albumin,2 mg/c. c. ; sinomenine, 5 mg/c. c. ; decylamine 0.05 mg/c. c.
and *0.025 mg/c. c. Tyrode medium, at 37.5° C.
Concn.of Percentage histamine released
Releaser Inhibitor inhibitor Releaser
\
Releaser (a-b)/(a)
(%) alone + inhibitor X100
(a) (b)
Antigen #32 1 8.5 10 -15
5.8 5.6 3.4
9.9 11 0.1
0.1 5.8 2.2 62
13 5.1 60
9.9 5.1 50
0.01 5.8 3.2 45
13 7.8 46
8.5 4.9 42
0.001 5.8 4.2 28
8.5 6.1 28
9.9 6.6 33
0.0001 5.8 5.5 5.1
8.5 7.8 8.2
9.9 8.4 15
0.00001 5.8 5.5 5.1
8.5 9.6 -11
9.9 9.5 4.0
Antigen #35 1 5.4 3.0 44
0.1 5.4 2.8 48
0.01 5.4 2.3 57
0.001 5.4 2.2 59
0.0001 5.4 4.8 11
0.00001 5.4 4.8 11
Antigen #42 1 9.9 4.1 58
0.1 13 6.0 53
0.01 13 7.6 41
0.001 13 9.1 30
0.0001 13 11 15
Antigen #58 1 6.3 3.1 51
0.1 13 8.2 36
6.3 3.8 40
0.01 13 12 7.6
6.3 5.0 21
0.001 13 12 7.6
6;3 5.7 9.5
10
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0.0001 13 12 7.6
6.3 5.7 9.5
0.00001 6.3 6.0 4.7
Sinomenine #32 0.1 6.7 4.6 31
19 7.8 59
0.01 6.7 4.1 40
12 5.8 50
19 9.0 53
0.001 14 9.2 34
14 .9.0. 36
0.0001 14 12 14
0.00001 14 13 7.0
Decylamine #32 0.1 41 36 12
0.01 41 37 9.7
0.001 41 41 0
0.0001 41 41 0
0.1* 17 15 8
0.01* 17 17 0
19 19 0
species, and therefore, it is necessary to carry on further investigation on in-
fluences of these compounds on the histamine release by other chemical sub-
stances and by allergic causes in order to correlate the anti-inflammatory and
anti-allergic effects of these compounds to histamine release.
Thus, by the methods previously reported by UCHIDA,16 experiments were
g120
I-
z
8100
ll..
0
~ 80CJ)
«
w
CJ) 60~
.-l
l.lJ
0::
W 40
z
~
~ 20CJ)
I
0
• Antlgen(E.A.2mg/cc)
o Slnomenlne (5mg/cc)
I-
CONT. 10-2 10-3 10- 4 10- 5 10-6 10-7
Fig. 7. Inhibition by # 32 of in vitro histamine release due to antigen and
sinomenine from chopped lung of the sensitized guinea pig. Abscissa, concentration
of # 32. Tyrode medium at 37°C.
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conducted to examine effects of these compounds on histamine release from
minced tissue of lung of anaphylactically sensitized guinea pigs, induced by
antigen (2 mg/c.c. of egg albumin) and also by chemical releasers such as sino-
menine hydrochloride17 (5 mg/c.c.) and decylamine hydrochloride (0.025-0.05
mg/c.c.).
The results are presented in Table 5. The anaphylactic release of histamine
was clearly inhibited by compounds, #32, #35, #42, and #58. The effect of
#32 was particularly prominent, showing it at the concentration as low as 10-6
(Fig. 7). This inhibitory effect increased along with the increase in concentra-
tion up to 10-3, but on further increase in the concentration it rather grew weaker.
Such a decrease in the inhibitory action may signify that this compound itself
releases histamine at a high concentration. Such a dual. action on histamine
release was reported with guaiazulene1 and antihistamines18•
Compound #32 showed a similar degree of inhibitory action on the his-
tamine release by both sinomenine and antigen but a weaker inhibition on the
release by decylamine.
E. Toxicity
1. Acute toxicity: Seven lumisantonin derivatives that had shown re-
latively marked anti-inflammatory and anti-allergic effects were submitted to the
experiment of acute toxicity in mice weighing 15-20 g. 0.5 c.c./10 g of 1 per cent
gum arabic suspension containing graded doses of the compounds was adminis-
tered orally and intraperitoneally. The mortality rate determined 48 hours after
the administration of the compounds is presented in Table 6. The toxicity of
compounds #29, #32, #49, and #54 proved to be lower than others and these
were well tolerated in the dose of 6 g/kg of oral administration and 4 g/kg of
intraperitoneal injection. The dose of 6 g/kg is the limit of administration in the
form of the suspension. Since LDllO of guaiazulene administered in the same form
Table 6. Acute toxicity of lumisantonin derivatives. no. deaths/no. tests,
determined 48 hours after medication.
Oral (mg/kg) Intraperitoneal (mg/kg) Subcutaneous(mg/kg)Compd.
6000 14000 12000 11000 I 500 1200 6000 14000 12000 1 1000i500 I 200 2000 11000 [500
#28 4/4 2/3 0/3
I
4/4 3/3 1/3 0/3
#29 0/3 2/3 0/3
#32 0/3 0/3 2/6 0/4 0/4
#35 2/3 0/3 3/3 0/3
#42 3/3 1/3 0/3 0/3 3/3 1/3 0/3 2/3 0/3 0/3
#49 0/3 0/3 2/3 1/3 0/3
#54 0/3 0/3 0/3
#58 3/3 1/3 3/3 1/3 0/3
12
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was 1, 220 mg/kg in oral administration and 525 mg/kg in intra,peritoneal in-
jection/ six compounds excluding;;# 42 in the table are less toxic ithan guaiazu-
lene. Subcutaneous toxicity of compound # 42 which is soluble in olive oil was
tested but it was lower as compared with the case of oral administration.
In mice given a large doset(6 g/kg) of compounds # 32, ~'49 and # 54
intraperitoneally only the symptoms observable were a diminution of active
movement and gradual prostration, and death occurred in some mice 24-48
hours afterwards. With toxic doses of other members,spme manifestations due to
central stimulation such as acceleration of respiration, ~r~ction of tail, and gene-
raliZed tremor could be observed; 'and with 1 g/kg of #'~2, 2 g/kg of # 58 and
With 4 g/kg of # 28, # 29 and #~5 tonic and clonic type of c€1nvulsion was
recognized. In severe convulsion resultant~asphyxia killed the animals. The
properties of some of these compOunds as convulsant seem to ka~ been trans-
mitted from santonin from which they were derived. Compounds;fj: 32 and # 54,
however, rather resemble guaiazulene in that they induce motor paralysis with
large doses. These two compounds have two lumisantonins in a molecule and
this fact seems to be responsible for the difference in toxic symptoms from most
of other monolumisantonin derivatives.
. 2. Subchronic toxicity: Through a stomach tube 4 g/kg of compound
# 32 was administered once to 2 male and one female Wistar rats30 days old of
the same litter and their growth curves were compared with th~t of untreated
other rats of the same litter for the period of 3 weeks. There could be seen not
any difference between the two groups. Of 10 Wistar rats (32 days old, 6 males
and 4 females) of the other same ii'tter, 2 males and one female served as control
and to the others 250 mg, 500 mg and 1000 mg/kg of #32 were administered daily
threugh a stomach tube for 3 weeks. These litters receiving s~ch medications
showed apparently no abnormalit~ and their growth curves were-'practically the
same with controls as illustrated .in Fig. 8. These rats were sacrificed 3 days
after the last administration and submitted to autopsy. As the result, macrosco-
pic~lly no abnormality could be observed in all organs and also microscopically
no pathologic changes in the heart" lungs, liver, spleen, pancreas, kidneys and
adrenals. Blood taken just before'=,mtopsy showed no difference from that of
controls in the hemoglobin content, erythrocyte and white-cell co~nts as well as
classification findings nor any abnormally formed elements.
F. Other actions
1. Antipyretic and analgesic actions: The effect of_c,ompound # 32
in lowering the body temperatur~ of albino rats weighing 150-200 g in which
fever was elicited by subcutaneous injection of 0.5 c.c. of 5 per cent .witte peptone
incubated, was examined by BULLER, MIYA and CARR'S meth~l!l taking the
13
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Fig. 8. Growth curves of Wistar rats. Indicated· daily doses of #32 were given
through a stomach tube.
effect of aminopyrine as the control. The compound to be tested was admin-
istered intraperitoneally or orally 4 hours after the peptone injection. Room
temperature was kept at 20-22°C. The results are as shown in Fig. 9. In the
case of intraperitoneal injection of #32 with the doses of over 10 mg/kg anti-
pyretic action was definitely observed..Although its effect with larger doses was
weaker than that of aminopyrine, with doses of 10-50 mg/kg it was com-
parable to the latter. In the case of oral administration, however, the effect of
#32 was quite inferior to aminopyrine.
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Fig. 9. Antipyretic effects of # 32 and aminopyrine in the rats fevered by peptone.
A, aminopyrine (intraperitoneal); B, # 32 (intraperitoneal); C, aminopyrine and # 32 (by
mouth). Averages of triplicate experiments.
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As for the test of analgesic effect of this compound SANUKI and OHNO'S
hot-plate method~ (temperature of the plate, 55 0 ± 0.5 QC) and HAFFNER-HESSE'S
method2~ were employed, but by either method no analgesic effect could be
detected (Fig. 10).
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Fig. 10. Analgesic effect of # 32 and aminopyrine in mice with SANUKI and
OHNO'S hot-plate technique. Plate temperature, 55° ± 0.5°C; 12 mice to a group;
indicated doses are in terms of per 10 g body weight intraperitoneally.
2. Effect on intestine in vitro: Compounds #29, #32, #35, #42, #49,
# 54, and # 58 below the concentration of 10-3 did not give any clear-cut influ-
ence on the tone of the ileum strip of guinea pig suspended in a Tyrode solution
nor did they bring about gradual acceleration of peristalsis as demonstrated by
guaiazulene. Only compound #28 at the concentration above 5 X 10-4 elicited
contraction of the ileum. This was not antagonized by atropine or neoanterg.an.
Pretreatment with # 29, # 35, and # 42 at the concentration above 5 X 10-4 in-
hibited ileum spasm due to histamine (10-7), acetylcholine (10- 7), and BaC12
(2 X 10-4) in every case, and this inhibitory action was strongest in # 42.
DISCUSSION
The inhibitory effect on the increase in urinary histamine excretion of rat
due to ovomucoid was clearly detected in a considerable number of the lumisan-
tonin derivatives tested. In addition, some of them suppressed histamine release
from the lung of sensitized guinea pig induced by such chemical releasers as
sinomenine and decylamine. The fact that these compounds all inhibit histamine
release by a variety of releasers believed to have a different mechanism of action
15
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and that such an inhibition can be observed not only in vivo but also in vitro
indicates that it is undoubtedly local action at tissue level and in all probability
at cell level. On this point this action may be said to be similar to the action of
guaiazulene that had been previously reported.1
STERN and MILIN22, who made observations on azulene compounds suggestive
of their histamine-release inhibitory actiop., presumed that this action becomes
effective probably through activation of the pituitary-adrenal system, judging
from histologic pictures of hypophysis and adrenals. They have, however,
overlooked the fact that the histamine-release inhibitory action and anti-allergica~tion of azulene compounds can be observed by local application as well a&o in
vitro experiments with excised tissue, as ,already described precisely in our
report on guaiazulene.1 The action of lumisantonin derivatives as observed in
the present series' of experiments can be considered the same as that of IDIai-
azulene in so far as the foregoing findings are concerned. •
Most of these compounds that had suppre,ssed histamine release did markedly
inhibit anaphylactoid edema induced locally in the hind paw of rats by dextran.It is recognized that apart from histamine release 5-HT release16.23.24 and hya-
luronidase activation16 are also responsible for the occurrence of this dextran
edema. AccOl"ding to UDA,t6 one of us, in th~ inhibition of dextran edema due to
guaiazulene is -included the inhibition of histamine and 5-HT release as well as
anti-hyaluronidase action. Therefore, it must, be borne in mind that in the action
of lumisantonin derivatives aside from histamine release, effects on other ed~ma­
producing factors 'are also involved. Actually these compounds exhibited inhibi-
tion of various degrees on edemas induced by local inoculation of hyaluronidase,5·HT, and histamine other than dextran.
From the standpoint of clinical therapeutics, an inflammatory pathologic
states of practically important pattern may be due to allergic causes. Those
compounds that exhibited inhibitory effect on anaphylactoid edemas proved topossess also aFl undeniably clear-cut preventive action on passive cutaneous
anaphylaxis (peA). Since this allergic tissue reaction can be thought to be a
vascular response to integrated stimulation including unidentified mediatom26•26
besides released histamine, taking cognizance of the aforementioned findings,
these compounds must be thought to possess an action as to modify a certain
basic mechanism of reaction of tissue cells including capillary endothelium, in
response to these phlogogenic stimulation. It is possible that the action simH.ar
to this is included in the mechanism of inhibition of histamine release from cells.STERN et al.,22.27 ZIERZ and KIESSLING,28 and UDA2 reported that guai-
azulene was effective in preventing anaphylactfc shock in guinea pigs. UDA2in his
experiment called an attention to the fact that guaiazulene in this instance has
an action to slow down or make less firm the union of antigen and antibody.
16
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This action seems to be related to the effect of guaiazulene on PCA. According to
UnA, this action, however, constitutes only a minor part of the anti-anaphylactic
effect of guaiazulene, hence it can not be considered as practically so important.
Concerning lumisantoin derivatives, their influence on antigen-antibody interac-
tion remains still unclarified. However, judging from a marked inhibitory effect on
non-allergic inflammatory edema and on histamine release, after all an importance
should be placed on their direct action on tissue cells or capillary endothelium.
Of the lumisantonin derivatives that served as the materials in the present
experiments, the one that exhibited the strongest inhibition on PCA was com-
pound #32, methyl pyrophotosantoninate. This compound also revealed inhi·
bitory effect on dextran-, hyaluronidase-, histamine- and 5·HT edemas, all
being superior to guaiazulene. Moreover, among the members of these com-
pounds whose toxicity is lower than guaiazulene that of #32 is particularly
minimal. For example, in the rats administered with as a large dose as 1 gjkg
per day for 3 weeks there could be recognized no pathologic findings, this
proving that the compound is quite a less toxic substance the like of which has
no parallel among other known anti-inflammatory drugs. The fart that this
drug applied in the form of ointment at the concentration above 1: 3, 000
acted as to prevent PCA likewise substantiates in itself clinical utility value of
local application of this compound. From the experimental results concerning
its inhibitory effect on dextran edema, it is thought that the effect of oral
administration of this compound is considerably inferior to that of intra-
peritoneal injection as in the case with guaiazulene. We are now engaged in
modification of physical properties of the compound so as to make it more readily
absorbed by intestinal tract.
Compound #32, when administered parenterally, exhibited antipyretic
effect comparable to aminopyrine. This effect is undoubtedly more marked than
that of guiazulerie as observed in our previous experimentsl with the same
methods. In the case of oral administration its effect was much less than that
of aminopyrine. This ~eems in all probability to be due to the difference in ease
with which it is absorbed, depending upon the solubility of the substance. The
property of #32 differing from guaiazulene is in the point that this compound
does not increase peristalsis of isolated ileum. In spite of the fact that some
members of these derivatives showed a tendency to induce papaverine-like
depression or some spasm on ileum strip, compound #32 even at a high concentra-
tion did not reveal such an action. This seems to be an advantage over the
other members in its oral or systemic administration.
Be it as it may, from these results we anticipate therapeutic usefulness of
some of lumisantonin derivatives in a comparable degree as with guaiazulene.
It appears that compound #32 is more promising than guaiazulene in the use of
17
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local application for the treatment of some mucosal and cutaneous disorders of
inflammatory or allergic nature including gastritis and X-ray burns of skin for
which azulene compounds are indicated
SUMMARY
A number of derivatives and related compounds of lumisantonin were sub-
mitted to evaluatien for the action of histamine-release inhibition and anti-
inflammatory effect, as they structurally resemble guaiazulene in which these
actions had been proved. Nineteen compounds of these suppressed 50 per cent or
more of the increase in urinary excretion of histamine due to ovomucoid injection.
Five of them markedly inhibited all the edemas in the rat hind paws induced by
local inoculation of dextran, hyaluronidase, histamine, and 5-hydroxytryptamine.
Among these compounds, #32 (methyl pyrophotosantoninate) showed a superior
effe~t of inhibition than guaiazulene on all of these edemas, although the effects
of two drugs were comparable in the case of oral administration.
The members showing the edema inhibition likewise evidently protected
passive cutaneous anaphylaxis in guinea pigs by the intraperitoneal adminis-
tration; the effect of #32 was more marked than guaiazulene. This effect could
be observed when applied to the skin with an ointment containing the compouhd
in a concentration of more than O. 03 per cent 24 hours before.
In vitro histamine releases from the minced lung tissue of sensitized guinea
pig elicited by antigen and sinomenine were both inhibited by these compounds.
These findings indicate that the main sites of the histamine-release inhibition
and of the anti-inflammatory effect of these compounds are in the local tissue.
Compound #32 failed to show any analgesic effect in mice, but possessed a
considerable antipyretic action in rats. Some of the compounds in the tests depres-
sed guinea ·pig ileal strip while guaiazulene increased peristalsis, but any of these
actions was not recognized with #32 even in a high concentration. Most of the
members effective in inhibiting edemas as well as histamine release proved to be
less toxic than guaiazulene. #32 was well tolerated in the doses of 6 g/kg orally
and of 4 g/kg intraperitoneally by mice. The growth curves for three weeks of
rats practically did not deviate from that of the controls by daily administration
of 1 g/kg of #32 by stomach tube and there were no gross and microscopical
abnormalities in the main organs and blood.
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